http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
만성 골수성 백혈병에서 감마인터페론과 화학요법의 병용 : Gamma Interferon plus Chemotherapy Versus Chemotherpay Alone
박종원,안성홍,양진모,한치화,민우성,김춘추,김동집 대한내과학회 1990 대한내과학회지 Vol.38 No.1
The antiviral and antigrowth activity of interferon(IFN) makes this agent a promising approach to cacer therapy. Although IFN-γ is a structurally distinct molecule, this agent suppresses in vitro leukomic progenitor cells in a fashion similar to that of IFN-α. Therefore, we initiated a study of rIFN-γ at a dose of 0.2 ㎎/day(2×10^(6) u/day) subcutaneously in patients with chronic myelocytic leukimia(CML) for more than 12 months. 44 patients(chronic 29, advanced 15) entered in the study were evaluable. 18 out of 29(62.1%) patients in chronic phase showed hematological complete response and 3(20%) of 15 advanced diseases returned to chronic phase. 25 patients who have had chemotherapy only were used as control. Among 25 of them, 22 were in chronic phases, only 3 could enjoy hematological complete response(13.6%). 3 in advanced disease had no response with chemotherapy alone. In responding patients, the IFN-γ reduced the requirment of hydroxyurea and prolonged the duration of responses. Approximately 55.6% of rIFN-γ induced complete hematologic responders showed cytogentic improvement(complete remission; 16.7% partial remission; 38. 9%). The age and sex did not effect the response rate to the IFN-γ therapy. But, we observed a tendency of incereased response rate by early introduction of IFN-y to the chronic phase of CML. Although our observatron period was short, our result indicated that IFN-γ effect synergistically to the conventional chemotherpy for the patient with CML.